Matt Browne

Matt Browne's practice focuses on transactional and general corporate matters, with Matt typically serving as his client’s first point of contact at Cooley for all matters and regularly working with them on mergers and acquisitions, public and private securities offerings, public company reporting and disclosure issues, corporate governance matters and other commercial matters.

Matt’s clients include companies in the software, cybersecurity, healthcare, semiconductor, financial technology, cleantech, consumer products, medical device, diagnostics, biotechnology, and internet commerce spaces.

Matt's recent engagements include:

• AgileThought: de-SPAC transaction with LIV Capital Acquisition Corp.
• Confluence Technologies: Representation of Confluence Technologies’ management team in acquisition of company by Clearlake Capital
• Billtrust: de-SPAC transaction with South Mountain Merger Corp.
• xMatters: Sale to Everbridge
• AttackIQ: $44 million Series C financing
• Cortica: $60 million Series C financing
• Paradigm Diagnostics: Sale to Exact Sciences
• Viomics: Sale to Exact Sciences
• Verb Surgical: Sale to Johnson & Johnson
• TPG Sixth Street Partners: Sale of Kadcyla® royalties
• MedImpact: Cash tender offer for all outstanding equity held by non-affiliates

Matt is on the board of directors and executive committee of the Corporate Directors Forum, is on the executive committee of Connect San Diego, and is a former trustee of the Sanford Burnham Prebys Medical Discovery Institute. He is a member of Cooley's risk management committee and a former member of Cooley's opinion committee and partnership nominating committee.

Matt joined Cooley in 1999.  Prior to joining Cooley, Matt was an associate at Cravath, Swaine & Moore in New York.